Lifesaving liver disease medicines
Versantis develops a new generation of liver disease therapeutics and diagnostics.
We are committed to the translation of life-saving therapies for acute hepatic diseases, where the medical need is dramatically high.
A life-saving therapy
Versantis’ lead product candidate, VS-01, is being investigated in a Phase 1b clinical trial for the acute treatment of decompensated cirrhosis. VS-01 was granted orphan drug designations from both FDA and EMA and has the potential to target the liver deficiencies associated with the higher unmet need and cost of care, such as acute hepatic encephalopathy (acute HE), acute-on-chronic liver failure (ACLF), or urea cycle disorders (UCDs). The versatile mechanism of action of VS-01 can simultaneously support multiple affected organ functions (liver, kidneys, brain), encourage liver regeneration, and save patients’ lives.
Versantis closes an oversubscribed CHF 16M Series B to advance VS-01 to Phase 2a!
Versantis scored #2 BEST BIOTECH in the in TOP100 Swiss Startups ranking!
Versantis featured in Handelszeitung
Versantis receives both regulatory and ethics approval to start its first-in-human study! VS-01's clinical journey goes on!
> read the full article